As personalized medicine is currently gaining popularity, our findings for crizotinib may contribute to effective prescriptions to prevent further development of drug-resistant cancer in lung cancer patients who have c-MET and ALK mutation phenotypes. The gene discussed is MET; the disease is cancer.